eb84c7b1-da0d-48cb-ba8b-0c1f2b3df4cd
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.500
- ALLOGRAFT_REJECTION+0.400
- IL6_JAK_STAT3_SIGNALING+0.400
- INTERFERON_GAMMA_RESPONSE+0.400
- COMPLEMENT+0.100
- INFLAMMATORY_RESPONSE+0.100
- KRAS_SIGNALING_DN+0.100
- BILE_ACID_METABOLISM+0.000
- COAGULATION+0.000
- IL2_STAT5_SIGNALING+0.000
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.500
- ADIPOGENESIS-0.400
- CHOLESTEROL_HOMEOSTASIS-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- HYPOXIA-0.400
- MTORC1_SIGNALING-0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.400
- ESTROGEN_RESPONSE_EARLY-0.300
- ESTROGEN_RESPONSE_LATE-0.300
- FATTY_ACID_METABOLISM-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934818 | — | — | 0.884 |
| 2 | AUR-AG0J-TTP1-A-1-0-R-A741-41 | — | D | 0.878 |
| 3 | be8d8236-4ebc-46de-a4fd-a901fec1cdce | — | — | 0.857 |
| 4 | SRR12202481 | — | — | 0.856 |
| 5 | MBCProject_1819_T2B_RNA | — | D | 0.852 |
| 6 | TCGA-MN-A4N5-01A-11R-A24X-07 | — | cohortA1 | 0.847 |
| 7 | X65f5effa.07f7.4ed3.9e0a.3a0d9d451474 | — | cohortA1 | 0.843 |
| 8 | BS_FX2P2WEG | high-grade glioma | — | 0.843 |
| 9 | MNG1248 | — | — | 0.842 |
| 10 | TCGA-GM-A2DO-01A-11R-A18M-07 | — | D | 0.842 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 7 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.100 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |